Abstract:Background: A diagnosis of hereditary angioedema (HAE) with normal C1 esterase inhibitor (HAE-nl-C1-INH) can be challenging and pharmacologic management is not well defined. Objective: The objective was to discuss practical considerations in the clinical management of HAE-nl-C1-INH by using illustrative clinical vignettes to highlight and/or address select challenges. Methods: This was a narrative review. Results: Symptoms of HAE-nl-C1-INH overlap with HAE types I and II; the heterogeneity of presentation and symptom burden are diagnostic challenges. A patient history, with particular attention to whether urticaria or other symptoms of mast cell mediator release are present, is important because such symptoms would strongly suggest a mast cell‐mediated pathway. A family history of angioedema is informative but a lack thereof does not rule out diagnosis. Expected laboratory findings would be normal for C4, C1-INH level and function, and Complement 1q; a genetic mutational analysis may be helpful, but current assays do not include all known mutations; most cases are categorized as unknown. To align with guideline-directed treatment approaches, the following stepwise approach is suggested for suspected HAE-nl-C1-INH: (1) thoroughly investigate the possibility of response to histaminergic and/or mast cell‐targeting treatments; (2) if patients with normal C4, C1-INH level and/or function fail adequate trials with histamine/mast cell-directed therapy or have a mutation that suggests bradykinin pathway involvement, follow HAE type I and II treatment guidelines. Response to medications approved for HAE types I/II provides compelling support for a high clinical suspicion of HAE-nl-C1-INH. De-labeling an HAE-nl-C1-INH diagnosis may be appropriate if the initial diagnosis was made without adequate evaluation or if new information and/or testing indicates that the patient does not actually have HAE. Conclusion: Key unmet needs in HAE-nl-C1-INH include lack of confirmatory biomarker(s) for diagnosis and lack of prospective controlled clinical studies of pharmacologic products in this patient population.

Summary and future of medicine for hereditary angioedema

The Future of Therapeutic Options for Hereditary Angioedema

Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches

Hereditary angioedema: current therapeutic management and future approaches

Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology

Targeting factor XIIa for therapeutic interference with hereditary angioedema

Advent of oral medications for the treatment of hereditary angioedema

Unveiling the Complexities of Hereditary Angioedema

Hereditary angioedema classification: Expanding knowledge by genotyping and endotyping

Hereditary angioedema with normal C1 esterase inhibitor: Current paradigms and clinical dilemmas

Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

Long-term Prophylaxis with Androgens in the Management of Hereditary Angioedema (HAE) in Emerging Countries

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Expert Perspectives on Hereditary Angioedema: Key Areas for Advancements in Care across the Patient Journey

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

Pathophysiology and underlying mechanisms in Hereditary Angioedema

Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus

[Long-term prophylactic therapy combined with on-demand therapy for the control of hereditary angioedema--Comment on the 2021 edition of the international WAO/EAACI guideline for the management of hereditary angioedema]

Consensus on treatment goals in hereditary angioedema: A global Delphi initiative

Molecular Genetics Progress of Hereditary Angioedema